Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05126758 · ClinicalTrials.gov registry record · Phase 3
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
A Phase 3 study of Nervous System Diseases and Neuromuscular Diseases, sponsored by Capricor.
- Active
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
- 20
- Study locations
NCT05126758 is a Phase 3 study of Nervous System Diseases and Neuromuscular Diseases that is active but no longer recruiting, run by Capricor. The registered enrollment target is 106 participants, below the 319-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT05126758, a Phase 3 study of Nervous System Diseases and Neuromuscular Diseases, is active but no longer recruiting, sponsored by Capricor.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
- 20
- Study locations
Study Summary
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Deramiocel (CAP-1002)
Study Locations (20)
California
- UCSD Altman Clinical and Translational Research Institute - La Jolla
- Children's Hospital of Los Angeles, Division of Neurology - Los Angeles
- University of California, Davis - Sacramento
Missouri
- University of Missouri Health Care - Columbia
- Saint Louis Children's Hospital - St Louis
Ohio
- Akron Children's Hospital - Akron
- Cincinnati Children's Hospital Medical Center - Cincinnati
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Rare Disease Research, LLC - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05126758
The ClinicalTrials.gov registry entry for NCT05126758 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (67% lower). The listed sponsor is Capricor, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05126758 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT05126758 about?
NCT05126758 is a clinical study titled "A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy". HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulat...
What is the current status of trial NCT05126758?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2022-06-22. Estimated completion is 2026-12.
What conditions does trial NCT05126758 study?
This clinical trial studies the following conditions: Nervous System Diseases, Neuromuscular Diseases, Muscular Dystrophies, Muscular Diseases, Genetic Diseases, Inborn.
What interventions are being tested in trial NCT05126758?
The interventions under investigation include: Placebo (BIOLOGICAL), Deramiocel (CAP-1002) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05126758?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05126758 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nervous System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
COMPLETED · Phase 3
-
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
COMPLETED · Phase 3
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.